Premium
Inhibitory effects of formoterol and terbutaline on the development of late phase skin reactions
Author(s) -
GRÖNNEBERG R.,
ZETTERSTRÖM O.
Publication year - 1992
Publication title -
clinical and experimental allergy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.462
H-Index - 154
eISSN - 1365-2222
pISSN - 0954-7894
DOI - 10.1111/j.1365-2222.1992.tb03081.x
Subject(s) - terbutaline , degranulation , formoterol , immunoglobulin e , agonist , chemistry , budesonide , endocrinology , medicine , pharmacology , immunology , asthma , receptor , antibody
Summary The capacity of the β 2 ‐agonist terbutaline and the longer‐acting β 2 ‐agonist formoterol to suppress the development of late phase skin reactions to anti‐human IgE was evaluated in 17 healthy volunteers. Anti‐IgE injected intradermally per se induced an early weal and flare reaction, followed by a progressively increasing induration, the LCR, with a duration of ≥ 24 hr. The LCR was inhibited by 40% when the weal was infiltrated with formoterol 250 ng 30 min after challenge ( n =9, P < 0.01). The same anti‐LCR effect was achieved by compensating for the shorter duration of action of terbutaline with repeated drug infiltration in 12.5 μg doses of the weal produced by anti‐IgE up to 3½ hr after challenge ( n =8). The data support the hypothesis that β 2 ‐agonists, both short‐and long‐acting, inhibit IgE‐dependent LCRs by preferentially interacting with inflammatory events after the initial mast cell degranulation